These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9030493)

  • 1. The importance of genetic and nutritional factors in responses to vitamin D and its analogs in osteoporotic patients.
    Nakamura T
    Calcif Tissue Int; 1997 Jan; 60(1):119-23. PubMed ID: 9030493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of vitamin D, its metabolites, and analogs in the management of osteoporosis.
    Bikle DD
    Rheum Dis Clin North Am; 1994 Aug; 20(3):759-75. PubMed ID: 7984788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
    Jones G; Hogan DB; Yendt E; Hanley DA
    CMAJ; 1996 Oct; 155(7):955-61. PubMed ID: 8837546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between the effect of eldecalcitol and serum 25(OH)D level.
    Takano T; Kondo S; Saito H; Matsumoto T;
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():124-7. PubMed ID: 24240066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D physiology.
    Lips P
    Prog Biophys Mol Biol; 2006 Sep; 92(1):4-8. PubMed ID: 16563471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing fracture risk with calcium and vitamin D.
    Lips P; Bouillon R; van Schoor NM; Vanderschueren D; Verschueren S; Kuchuk N; Milisen K; Boonen S
    Clin Endocrinol (Oxf); 2010 Sep; 73(3):277-85. PubMed ID: 20796001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
    Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
    Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a differential response to alfacalcidol and vitamin D in the treatment of osteoporosis?
    Francis RM
    Calcif Tissue Int; 1997 Jan; 60(1):111-4. PubMed ID: 9030491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 4. Calcium nutrition and osteoporosis.
    Murray TM
    CMAJ; 1996 Oct; 155(7):935-9. PubMed ID: 8837543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy.
    Lau KH; Baylink DJ
    Calcif Tissue Int; 1999 Oct; 65(4):295-306. PubMed ID: 10485982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.
    Matsumoto T; Ito M; Hayashi Y; Hirota T; Tanigawara Y; Sone T; Fukunaga M; Shiraki M; Nakamura T
    Bone; 2011 Oct; 49(4):605-12. PubMed ID: 21784190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects.
    Matsumoto T; Kubodera N
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):584-6. PubMed ID: 17298881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD; Faber H; Fahramand P; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Serum 25(OH)D
    Nakamura Y; Uchiyama S; Kamimura M; Ikegami S; Komatsu M; Kato H
    Tohoku J Exp Med; 2017 Jul; 242(3):241-246. PubMed ID: 28740036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eldecalcitol for the treatment of osteoporosis.
    Noguchi Y; Kawate H; Nomura M; Takayanagi R
    Clin Interv Aging; 2013; 8():1313-21. PubMed ID: 24101867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advantages of active vitamin D metabolites in the treatment of osteoporosis as compared with calciferol].
    Zofková I
    Vnitr Lek; 2001 Feb; 47(2):99-100. PubMed ID: 15635854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.